Filtered By:
Condition: Thrombosis
Education: Education
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 840 results found since Jan 2013.
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review.
CONCLUSION: Interventions designed to improve appropriate prescription of OACs in eligible AF patients for stroke prevention can be effective. Successful approaches include education of HCPs; implementation of local guidelines; interdisciplinary medical care programs educating both HCPs and patients and persuasive interventions utilizing peer-group experts. Protocol registration: PROSPERO (CRD42016039654).
PMID: 30669165 [PubMed - in process]
Source: Thrombosis and Haemostasis - January 24, 2019 Category: Hematology Authors: Pritchett RV, Bem D, Turner GM, Thomas GN, Clarke JL, Fellows R, Lane DA, Jolly K Tags: Thromb Haemost Source Type: research
Perinatal thrombosis: implications for mothers and neonates.
Authors: O'Brien SH
Abstract
Stroke is more likely to occur in the perinatal period than any other time in childhood, and these events can lead to a lifetime of intellectual and motor disabilities, epilepsy, and behavioral challenges. This review describes the epidemiology and natural history of perinatal arterial ischemic stroke (PAIS) and cerebral sinovenous thrombosis (CSVT), risk factors for these complications, recent evidence regarding treatment strategies, and current gaps in knowledge. Existing evidence demonstrates the multifactorial etiology of symptomatic ischemic stroke in neonates, which includes a com...
Source: Hematology ASH Education Program - December 10, 2015 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
‘Ten Commandments’ of the EHRA Guide for the Use of NOACs in AF
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. In 2013, the first “EHRA Practical Guide” was published to provide practical guidance for situations; an update was published in 2015. Below ...
Source: European Heart Journal - April 21, 2018 Category: Cardiology Source Type: research
P83 The relationship of functional outcome after mechanical thrombectomy and serum glucose is partially mediated by edema formation
ConclusionEdema formation explains 15% of the total adverse effects of high blood glucose levels. Major pathways might include other direct effects of high blood glucose, such as altered vessel wall and thrombus characteristics and higher thrombogenicity of the cerebral blood flow.ReferencesThorén, M., et al. "Predictors for Cerebral Edema in Acute Ischemic Stroke Treated with Intravenous Thrombolysis." Stroke 2017;48(9): 2464–2471. Do you have any conflict of interest to declare?: YesConflict of Interest StatementHelge Kniep is a consultant for Eppdata.Jens Fiehler received research support from: German Minis...
Source: Journal of NeuroInterventional Surgery - August 29, 2022 Category: Neurosurgery Authors: Kniep, H., Meyer, L., Bechstein, M., Hanning, U., Fiehler, J., Broocks, G. Tags: 14th Congress of the European Society of Minimally Invasive Neurological Therapy 2022 Meeting Abstracts Source Type: research
Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5 mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research
Non-Vitamin K antagonist Oral Anticoagulants: Impact of Non-adherence and Discontinuation.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Lip GYH
Abstract
INTRODUCTION: Non-Vitamin K Oral Anticoagulants (NOACs) are at least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality in atrial fibrillation (AF). These "fixed-dose regimen" drugs are characterized by not requiring routine monitoring or dosage adjustment. Stroke prevention with OAC is indicated in AF patients with CHA2DS2-VASc ≥2 (≥3 in females) and NOACs are recommended in preference to VKAs. However, underuse, premature discontinuation of treatment and non-adherence to guidelines is common, ...
Source: Expert Opinion on Drug Safety - July 6, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
A Copernican Approach to Brain Advancement: The Paradigm of Allostatic Orchestration
The objective of this presentation is to explore historical, scientific, interventional, and other differences between the two paradigms, so that innovators, researchers, practitioners, policy-makers, patients, end-users, and others can gain clarity with respect to both the explicit and implicit assumptions associated with brain advancement agendas of any kind.
Over the course of three decades, a series of brain-centric, evolution-inspired insights have been articulated with increasing refinement, as principles of allostasis (Sterling and Eyer, 1988; Sterling, 2004, 2012, 2014). Allostasis recognizes that the role of the ...
Source: Frontiers in Human Neuroscience - April 25, 2019 Category: Neuroscience Source Type: research
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
Authors: Kimpton M, Siegal DM
Abstract
A 77-year-old man with atrial fibrillation and a CHA2DS2Vasc score of 6 for hypertension, age, diabetes, and previous stroke is brought to the emergency department with decreased level of consciousness. He is anticoagulated with rivaroxaban (a direct oral factor Xa inhibitor [FXaI]) and received his last dose about 4 hours before presentation. Urgent computed tomography of the head shows intracerebral hemorrhage. Because of his previous stroke, the patient's family is concerned about treating the bleed with pharmacological agents that may increase the risk of stroke. What are ...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Gene breakthrough boosts hope of drug for blood diseases
Discovery could prevent lethal blood clots and help children with rare platelet function disorderNoah Edwards is four years old and suffers from a disorder that prevents his blood from clotting. He bleeds profusely when cut and his face and body are easily bruised.His condition, called platelet function disorder, is a constant worry for his mother, Ruby. However, thanks to Noah's involvement in a remarkable project, funded by the British Heart Foundation, his prospects of leading a normal life have received a major boost.Researchers at Birmingham University have uncovered the genetic roots of platelet function disorder, a ...
Source: Guardian Unlimited Science - January 13, 2013 Category: Science Authors: Robin McKie Tags: University of Birmingham Genetics Biology News Medical research Higher education UK news The Observer Science Source Type: news
Epidemiologic and clinical data linking factors XI and XII to thrombosis.
Authors: Key NS
Abstract
Currently available evidence supports the contention that elevated levels of factor XI (fXI) are associated with a greater risk of venous thromboembolism and ischemic stroke, but, less convincingly, with myocardial infarction. Conversely, reduced plasma levels of fXI seem to offer some protection from venous thromboembolism and stroke, but not myocardial infarction. Factor XI-deficient patients are at risk for certain types of bleeding, particularly posttraumatic hemorrhage on mucosal surfaces where there is a high endogenous fibrinolytic activity. In contrast, the situation with fXII in hu...
Source: Hematology ASH Education Program - February 20, 2015 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
CE: Atrial Fibrillation: Updated Management Guidelines and Nursing Implications.
This article reviews the recently updated guideline for the management of atrial fibrillation, issued jointly by the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society. It focuses on the prevention of thromboembolism and on symptom control, and stresses the importance of patient adherence to treatment plans in order to ensure better outcomes.
PMID: 25859746 [PubMed - as supplied by publisher]
Source: The American Journal of Nursing - April 9, 2015 Category: Nursing Authors: Cutugno CL Tags: Am J Nurs Source Type: research
Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Learning objectives Understand the importance of venous thrombosis in cardiovascular medicine. Appreciate the mode of action of different oral anticoagulants. Recall the uses, risks and benefits of each non-vitamin K antagonist oral anticoagulants. Introduction Thrombosis is the common pathophysiology responsible for ischaemic heart disease, ischaemic stroke and venous thromboembolism (VTE), and a major contributor to the global disease burden.1 This effect is markedly more pronounced by considering the view that cancer is also a thrombotic disease.2 3 Cardiovascular disease (CVD, manifesting as acute coronary syndromes, m...
Source: Heart - June 5, 2016 Category: Cardiology Authors: Blann, A. D., Lip, G. Y. H. Tags: Education in Heart, Drugs: cardiovascular system, Acute coronary syndromes, Venous thromboembolism, Epidemiology Source Type: research
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
This report is based on findings from the Anticoagulation Education Task Force, which brought together patient groups and professionals representing different medical specialties with an interest in patient safety and expertise in AF, VTE, stroke, anticoagulation, and reversal agents, to discuss the current status of anticoagulation reversal and fundamental changes in management of bleeding associated with DOACs occasioned by the approval of idarucizumab, a specific reversal agent for dabigatran, as well as recent clinical data on specific reversal agents for factor Xa inhibitors. Recommendations are given for when there i...
Source: Thrombosis and Haemostasis - August 3, 2016 Category: Hematology Authors: Ageno W, Büller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ Tags: Thromb Haemost Source Type: research
Hemostasis biomarkers and risk of sepsis: the REGARDS cohort
ConclusionBaseline fibrinogen, FIX and FXI levels are associated with future episodes of sepsis. Hemostasis biomarkers may provide targets for sepsis mitigation or prevention.
Source: Journal of Thrombosis and Haemostasis - September 22, 2016 Category: Hematology Authors: J. X. Moore, N. A. Zakai, M. Mahalingam, R. L. Griffin, M. R. Irvin, M. M. Safford, J. W. Baddley, H. E. Wang Tags: Original Article Source Type: research
